Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I [PDF]
Frontiers in Immunology, 2018 Antiphospholipid antibodies (aPL), the serological hallmark of antiphospholipid syndrome (APS), are a heterogeneous group of autoantibodies raised against circulating blood proteins.
Thomas McDonnell +7 more
doaj +9 more sources
Methodology of generation and purification of anti-beta 2 glycoprotein I antibodies [PDF]
MethodsX, 2019 In this Method Article we are showing the methodology for generation and purification of Anti-Beta 2 Glycoprotein I (β2GPI) antibodies. First β2GPI was purified from human plasma, and recognized by Western Blot and anti-β2GPI antibodies of serum from ...
Marcelo Alarcon +4 more
doaj +5 more sources
The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome [PDF]
Antibodies, 2016 Antiphospholipid syndrome (APS) is a thrombophilic disorder that classically presents with vascular thrombosis and/or obstetric complications. APS is associated with antiphospholipid antibodies: a heterogeneous group of autoantibodies that are directed ...
Anna Brusch
doaj +6 more sources
Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation [PDF]
Frontiers in Immunology, 2019 Background: The presence of anti-Beta 2 glycoprotein antibodies (aB2GP1) of IgA isotype is common in patients with functional impairment of the organs in which B2GP1 is elaborated.
Manuel Serrano +9 more
doaj +3 more sources
PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome [PDF]
Frontiers in Immunology, 2022 Antiphospholipid syndrome (APS) is an autoimmune disorder in which autoantibodies cause clinical effects of vascular thrombosis and pregnancy morbidity. The only evidence-based treatments are anticoagulant medications such as warfarin and heparin.
Rohan Willis +7 more
doaj +2 more sources
Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome [PDF]
Frontiers in Immunology, 2023 Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent vascular thrombosis and miscarriages in the absence of known causes.
Claudia Grossi +12 more
doaj +2 more sources
Lysine residues control the conformational dynamics of beta 2-glycoprotein I [PDF]
Physical Chemistry Chemical Physics, 2020 One of the major problems in the study of the dynamics of proteins is the visualization of changing conformations that are important for processes ranging from enzyme catalysis to signaling. A protein exhibiting conformational dynamics is the soluble blood protein beta 2-glycoprotein I (beta2GPI), which exists in two conformations: the closed (circular)
Ina Buchholz +3 more
arxiv +7 more sources
Beta‐2‐Glycoprotein‐I Deficiency Could Precipitate an Antiphospholipid Syndrome‐like Prothrombotic Situation in Patients With Coronavirus Disease 2019 [PDF]
ACR Open Rheumatology, 2021 Objective Patients with coronavirus disease 2019 (COVID‐19) present coagulation abnormalities and thromboembolic events that resemble antiphospholipid syndrome (APS).
Manuel Serrano +17 more
doaj +2 more sources
Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding [PDF]
Scientific Reports, 2021 Beta-2-glycoprotein I (β2GPI) is a blood protein and the major antigen in the autoimmune disorder antiphospholipid syndrome (APS). β2GPI exists mainly in closed or open conformations and comprises of 11 disulfides distributed across five domains.
Ina Buchholz +11 more
doaj +2 more sources
B cell-derived anti-beta 2 glycoprotein I antibody mediates hyperhomocysteinemia-aggravated hypertensive glomerular lesions by triggering ferroptosis [PDF]
Signal Transduction and Targeted Therapy, 2023 Hyperhomocysteinemia (HHcy) is a risk factor for chronic kidney diseases (CKDs) that affects about 85% CKD patients. HHcy stimulates B cells to secrete pathological antibodies, although it is unknown whether this pathway mediates kidney injury.
Xing Du +16 more
doaj +2 more sources